Rohtak News Magazine

ARDS Market To Grow at a Considerable CAGR During the Study Period (2019-2032) | Key Companies – Genentech, MediciNova, Apeptico, Edesa, BioMarck, Athersys, Healios, Windtree Therapeutics

 Breaking News
  • No posts were found

ARDS Market To Grow at a Considerable CAGR During the Study Period (2019-2032) | Key Companies – Genentech, MediciNova, Apeptico, Edesa, BioMarck, Athersys, Healios, Windtree Therapeutics

August 23
22:01 2022
ARDS Market To Grow at a Considerable CAGR During the Study Period (2019-2032) | Key Companies - Genentech, MediciNova, Apeptico, Edesa, BioMarck, Athersys, Healios, Windtree Therapeutics
As per DelveInsight, the ARDS market is expected to grow by 2032 owing to the increasing number of patients and the high demand for novel therapies.

DelveInsight’s “Acute respiratory distress syndrome (ARDS) marketreport, delivers an in-depth understanding of ARDS, historical and forecasted epidemiology, and the market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), Japan, and China.

Key takeaways from the ARDS  Market Report

  • DelveInsight analysis shows that the ARDS market was approximately 1,173 USD million in the 7MM in 2021.

  • As per our estimates, the prevalence of the ARDS market was more than 1,088,015 cases in the 7MM in 2021.

  • Leading companies in the market include Edesa/Light Chain Bio, BioMarck Pharmaceuticals, Direct Biologics, Athersys/Healios, Windtree Therapeutics, Boehringer Ingelheim//Genentech, MediciNova, Apeptico Forschung und Entwicklung GmbH, Mesoblast, and others are developing novel migraine drugs which can be available in the migraine market in the upcoming years.

  • Promising emerging ARDS therapies in the pipeline include EB05 and EB06, BIO-11006, ExoFlo (DB-001), MultiStem, Lucinactant (KL4 surfactant), Alteplase, MN-166 (ibudilast), Solnatide (AP301), Remestemcel-L, and others. 

  • The current understanding of IgA nephropathy has greatly improved in recent decades. It has led to advancements, greater results, and newer therapies. 

ARDS Market

ARDS Overview 

Acute respiratory distress syndrome (ARDS) is a progressive disorder characterizing leakage of body fluids inside other compartments of the body, majorly the lungs. The causes of ARDS can be further divided into two categories, mainly direct and indirect injuries to the lungs. The direct injury to the lungs comprises pneumonia, aspiration, trauma, and others. Whereas the indirect injuries to the lung include inflammation of the pancreas, severe infection, blood transfusions, burns, and medication reactions. The signs and symptoms that can be observed in ARDS patients include shortness of breath, cough, and fever. 

ARDS Epidemiology Segmentation

As per Delveinsight, the prevalence of ARDS was 1,088,015 cases in the 7MM in 2021. Among the EU5, Germany had the highest prevalent cases in 2021. Whereas Spain had the least prevalent cases. 

The epidemiology analysis of the market during the study period (2019-2032) is segmented into

  • Total Incident Population 

  • Severity-specific Cases of ARDS 

  • Incident Cases of ARDS by Risk Factors 

To read more about the epidemiology of ARDS, visit ARDS Epidemiology Analysis

ARDS Treatment Market

Treatment of acute respiratory distress syndrome is supportive and includes mechanical ventilation, prophylaxis for stress ulcers and venous thromboembolism, nutritional support, and treatment of the underlying injury. Low tidal volume, high positive end-expiratory pressure, and conservative fluid therapy may improve outcomes. It is important to identify and treat any underlying infections with antibiotics targeted at culture sensitivities. Despite decades of research, treatment options for ARDS are restricted. Supportive care with mechanical ventilation remains the mainstay of management. There are relatively few treatments available for ARDS. 

Other treatment options, to which the patients with ARDS are generally subjected include supplemental oxygen, prone positioning, use of paralytics, fluid management, and a technique called positive end-expiratory pressure (PEEP) to help push the fluid out of air sacs. These are combined with continuing treatment of the original illness or injury. Because people with ARDS are less able to fight lung infections, they may develop bacterial pneumonia during the illness. Antibiotics are given to fight infection. Also, supportive treatment, such as intravenous fluid or food, may be needed. 

ARDS Pipeline Therapies and Key Companies 

  • Edesa/Light Chain Bio- EB05 and EB06

  • BioMarck Pharmaceuticals- BIO-11006

  • Direct Biologics- ExoFlo (DB-001)   

  • Athersys/Healios- MultiStem

  • Windtree Therapeutics- Lucinactant (KL4 surfactant) 

  • Boehringer Ingelheim//Genentech- Alteplase 

  • MediciNova- MN-166 (ibudilast) 

  • Apeptico Forschung und Entwicklung GmbH- Solnatide (AP301)

  • Mesoblast- Remestemcel-L

ARDS Market Dynamics

Premium-price agents such as stem cell therapies and other pipeline candidates with a better clinical profile is expected to dominate the ARDS market. Moreover, several molecules are being evaluated and investigated by several pharmaceutical companies to strengthen the pipeline, thereby raising the hope for an efficacious therapy in the near future. The increasing of patients with ARDS stimulates the research and development of the drug and pave the way for newer products.

However, the treatments of ARDS have always been difficult because the underlying disease process is incompletely understood.  Supportive care with mechanical ventilation remains the mainstay of management. Most ARDS cases are not diagnosed at any time during a patient’s stay in the intensive care unit (ICU), leading to delayed diagnosis. Moreover, most of the emerging drugs have failed during clinical trials.

Scope of the ARDS  Market Report

  • Study Period: 2019–2032

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom)]. 

  • Key ARDS  Companies: Edesa/Light Chain Bio, BioMarck Pharmaceuticals, Direct Biologics, Athersys/Healios, Windtree Therapeutics, Boehringer Ingelheim//Genentech, MediciNova, Apeptico Forschung und Entwicklung GmbH, Mesoblast, and others

  • Key ARDS  Therapies: EB05 and EB06, BIO-11006, ExoFlo (DB-001), MultiStem, Lucinactant (KL4 surfactant), Alteplase, MN-166 (ibudilast), Solnatide (AP301), Remestemcel-L, and others

  • Therapeutic Assessment: ARDS marketed and emerging therapies

  • ARDS  Market Dynamics:  ARDS market drivers and barriers.

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies.

  • Unmet Needs, KOL’s views, Analyst’s views, ARDS  Market Access and Reimbursement

Table of Contents

1. ARDS Market Key Insights

2. ARDS Market Report Introduction

3. ARDS Market Overview at a Glance

4. ARDS Market Executive Summary

5. Disease Background and Overview

6. ARDS Treatment and Management

7. ARDS Epidemiology and Patient Population

8. Patient Journey

9. ARDS Off-Label Therapies

10. ARDS Emerging Drugs

11. 7 Major ARDS Market Analysis

12. ARDS Market Outlook

13. Potential of Current and Emerging Therapies

14. KOL Views

15. ARDS Market Drivers

16. ARDS Market Barriers

17. Unmet Needs

18. SWOT Analysis

19. Appendix

20. DelveInsight Capabilities

21. Disclaimer

22. About DelveInsight

Download the Sample Pages @ ARDS Therapeutics Market Assessment

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.  Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Related Articles